Letter to the editor: Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer
- PMID: 32666003
- PMCID: PMC7329646
- DOI: 10.4111/icu.2020.61.4.452
Letter to the editor: Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer
Conflict of interest statement
CONFLICTS OF INTEREST: The authors have nothing to disclose.
Comment on
-
Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.Eur Urol. 2009 Feb;55(2):310-20. doi: 10.1016/j.eururo.2008.09.024. Epub 2008 Sep 24. Eur Urol. 2009. PMID: 18838208 Review.
-
Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer.Investig Clin Urol. 2020 May;61(3):242-249. doi: 10.4111/icu.2020.61.3.242. Epub 2020 Apr 27. Investig Clin Urol. 2020. PMID: 32377599 Free PMC article. Review.
References
-
- Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55:310–320. - PubMed
-
- Morgentaler A, Benesh JA, Denes BS, Kan-Dobrosky N, Harb D, Miller MG. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months. J Sex Med. 2014;11:2818–2825. - PubMed
-
- Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol. 2011;186:1005–1011. - PubMed
-
- Rastrelli G, Corona G, Vignozzi L, Maseroli E, Silverii A, Monami M, et al. Serum PSA as a predictor of testosterone deficiency. J Sex Med. 2013;10:2518–2528. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
